Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer

Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer

BackgroundOver the past decade, progress in the diagnosis and treatment of Non-Small Cell Lung Cancer (NSCLC) has led to the identification of many targeted mutations. This has enhanced PFS and OS in both advanced and early-stage NSCLC. The current standard of care for stage III NSCLC varies, and it...

Full description

Bibliographic Details
Main Authors: Waleed Kian, Belal Krayim, Betsy Giles, Nasim A. Elkiaan, Amjad Idris, Daniel Fink, Nir Peled, Laila C. Roisman
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
brigatinib
osimertinib
neoadjuvant
ALK
EGFR
lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1286116/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1286116/full

Similar Items